Spesolimab (BI 655130): IL36R antibody
Phase 2
Indication: Netherton Syndrome (NS)
Spesolimab is a first-in class anti-IL-36 receptor antibody from Boehringer Ingelheim´s own research. It is being investigated in multiple potentially IL-36 pathway mediated auto-inflammatory diseases with generalized pustular psoriasis (GPP) as the lead indication. Spesolimab is also under investigation for the treatment of other IL-36 mediated skin diseases, such as Netherton Syndrome (NS) and Hidradenitis Suppurativa (HS).